Therefore, O-GlcNAc is a highly interesting and versatile PTM that could be an attractive target for new anti-cancer drug development, particularly in the context of oncogenic STAT5A in hematopoietic cancers. The gene discussed is STAT5A; the disease is hematopoietic and lymphoid cell neoplasm.